Pfizer (NYSE:PFE) Stock Price Down 1.6% – Here’s Why

Pfizer Inc. (NYSE:PFE)’s share price dropped 1.6% during mid-day trading on Tuesday . The company traded as low as $26.47 and last traded at $26.6110. 36,266,027 shares changed hands during mid-day trading, a decline of 15% from the average daily volume of 42,457,094 shares. The stock had previously closed at $27.05.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock, adding 38,000 shares. The transaction may signal management’s confidence that the shares are undervalued and supports investor sentiment. Pfizer CEO Buys $1 Million of Stock
• Positive Sentiment: Pfizer raised its 2026 revenue outlook to approximately $60.5 billion-$62.5 billion. Stronger performance from recently launched and acquired products, including Seagen and Biohaven assets, is helping offset continued weakness in COVID-related products. Pfizer Higher 2026 Guidance and LITFULO Trial Results
• Positive Sentiment: Positive Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo strengthen Pfizer’s immunology pipeline and support the company’s strategy of building growth outside COVID products. Analysts also raised one 2026 EPS estimate to $2.95, close to the $2.98 consensus. Pfizer Chantix Settlement and LITFULO Results
• Neutral Sentiment: Analyst commentary remains focused on whether Pfizer’s launches, acquisitions and pipeline can drive sustained growth from 2029 onward. Broader market caution ahead of inflation data may limit near-term enthusiasm.
• Negative Sentiment: Second-quarter results included a $4.3 billion non-cash intangible-asset impairment and a reported net loss, highlighting portfolio and acquisition-related pressures.
• Negative Sentiment: Commentary warns that part of the 2026 guidance increase relies on products approaching patent expiration, raising concerns about future revenue durability. Pfizer also agreed to a $44 million Chantix settlement, while Arbutus filed patent lawsuits involving Pfizer and BioNTech. Pfizer Guidance and Patent Expiration Risks

Analyst Upgrades and Downgrades

PFE has been the subject of several research reports. Citigroup increased their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. BMO Capital Markets lowered their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. JPMorgan Chase & Co. dropped their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. CICC Research initiated coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. Finally, Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Stock Up 1.9%

The company has a market capitalization of $152.77 billion, a PE ratio of 35.22 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock’s 50 day moving average is $25.09 and its 200 day moving average is $26.18.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the firm posted $0.78 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.4%. Pfizer’s dividend payout ratio is currently 226.32%.

Institutional Trading of Pfizer

Several hedge funds and other institutional investors have recently bought and sold shares of PFE. Godfrey Financial Associates Inc. bought a new stake in Pfizer in the fourth quarter worth $26,000. Keb Asset Management LLC bought a new position in shares of Pfizer during the second quarter valued at $26,000. HFM Investment Advisors LLC increased its holdings in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares in the last quarter. Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the last quarter. Finally, Abound Financial LLC bought a new position in Pfizer in the 4th quarter worth about $31,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.